Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AZD9150 With or Without Durvalumab in Japanese Patients With Advanced Solid Tumors
jRCT2080223819Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of danvatirsen and durvalumab in Nonhematologic neoplasms and Non-hematologic malignancy (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD9150 with or without durvalumab, Pharmacokinetics of AZD9150 (± durvalumab) and 1 more. Started Feb 2018; status: completed.
02
Drugs
danvatirsendurvalumab
03
Conditions
Nonhematologic neoplasmsNon-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080223819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223819.